SubHero Banner

Imfinzi (durvalumab) – New drug approval

May 1, 2017 – AstraZeneca and its global biologics research and development arm, MedImmune, announced the FDA approval of Imfinzi (durvalumab), for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Download PDF